drugset / Trial / NCT05726175
Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Disitamab Vedotin combined with Penpulimab as neoadjuvant therapy in patients with HER2-low early or locally advanced breast cancer
Timeline
- Start
- 2023-03-01
- Primary completion
- 2024-07-31
- Completion
- 2024-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Penpulimab | Monoclonal antibody | 200 mg | Intravenous |